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Insulin like growth factor -2 (IGF-2), which is a secreted growth factor belonging to the Insulin 
signaling superfamily, plays an important role in embryonic growth but is epigenetically silenced 
on one parental allele in an imprinting mechanism in mammals post-birth. Loss of Imprinting 
(LOI) is the loss of this silencing mechanism, either spontaneous or inherited in nature, that 
results in a bi-allelic expression of IGF-2.  LOI causes increased growth, seen in the colon as 
abnormally elongated crypts and a 5 fold increase in the chance of developing colorectal cancer. 
In an in-vitro system, IGF-2 LOI cells show rapid growth via increased proliferation, 
overexpression of the Insulin-like growth factor-1 receptor (IGF-1R) that IGF-2 signals through 
and an increased sensitivity to the inhibition of the IGF-1R signaling when compared to wild-
type (WT) cells. It is shown here that IGF-2 LOI cells re-balance the two important kinases Akt 
and Erk that are activated downstream of the IGF-1R. While Erk signaling strength is increased, 
Akt signaling is attenuated in LOI cells in response to IGF-2 stimulation when compared to WT 
zcells. Since Erk activation is intricately linked to internalization of receptors, it is seen that LOI 
cells in conjunction with IGF-1R overexpression show increased internalization of activated IGF-
1R. While these two mechanisms contribute to increased Erk signaling, Akt activation is shown 
to depend on total receptor levels and recycling of the internalized receptors to the cell surface. 
Erk is also seen to mediate ubiquitination of IGF-1R thereby presumably increasing the rate of 
internalization and also to mediate the increase in transcriptional levels of IGF-1R over longer 
periods of time. Using a computational model of the IGF-2 signaling pathway, we show that 
increased Erk activation can sustain the LOI phenotype via increased internalization and 
transcriptional regulation of IGF-1R. The computational model is trained using the Akt and Erk 
activation profiles measured over time and tested on the profiles measured in WT cells. 
Interestingly, it is shown that the re-balance in the signaling strength of Akt and Erk signaling in 
LOI cells propagates down to the level of the anti and pro-apoptotic determinants Bax and Bcl-2. 
It is shown that while Akt regulates Bcl-2 signaling strength, Erk mediates Bax signaling through 
an as yet undetermined mechanism. The re-balance in the Bax and Bcl-2 levels of LOI cells is 
shown to make the cells more vulnerable to Bcl-2 inhibition by the computational model that is 
developed further to include Bax, Bcl-2 signaling. The computational model further predicts, 
based on the spread in the values of Bax and Bcl-2 in individual cells, a window of values of Akt 
inhibition for which LOI cells apoptose while WT cells don’t. This method of apoptosis is shown 
to involve activated Bax and the intrinsic apoptosis pathway of Caspase-9 and -3. Finally a 
stochastic model based on a random process called renewal process is developed to model the 
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Fundamentals of epigenetics :  Epigenetics refers to the set of changes, that doesn’t involve a 
change in the underlying DNA sequence, inherited during both mitosis and meiosis, that drives 
different phenotypes and cellular outcomes. Epigenetic changes like DNA methylation and 
histone modification can cause a wide array of changes in gene expression profiles in cells and 
are known to regulate most biological processes. A change in an epigenetic state or an 
establishment of a new epigenetic state can often require an extracellular signal that when 
propagated into the nucleus can change the chromatin state of the cell recruiting modifiers and 
a slew of cellular machinery thus establishing a stable heritable state. Such stable changes can 
also drive deregulated growth thereby making epigenetic changes a recurrent theme in all states 
of progression of various tumors and cancers. Thus epigenetic changes are not only involved in 
the fundamental processes of growth, differentiation and organization but can also drive 
deregulated growth and malignancy (Feinberg, 2013).  
Imprinting : Imprinted genes, which are found only in mammals and flowering plants, are genes 
that are epigenetically silenced depending on the parental nature of origin. For example, in 
humans, the maternal copy of IGF-2, a secreted hormone, is imprinted and epigenetically 
silenced while the paternal copy is expressed (Hu et al., 1997). In the case of IGF-2R, a mannose-
6-phosphate receptor, the reverse is the case as the maternal copy is expressed and the 
paternal copy is silenced. The epigenetic imprinting is achieved by a series of methylation marks 
that silences the gene. In humans the IGF-2 locus is found in a region of Chromosome 15 that 
contains many imprinted genes. The silencing is achieved via the binding of CTCF to the 
imprinting control region (ICR) of the H19 gene and a differentially methylated region (DMR-1). 
The binding of CTCF prevents access to the enhancer elements that are used for IGF-2 
expression. Thus imprinting is an epigenetic mechanism that tightly regulates the expression of 
genes (Ulaner et al., 2003a; Ulaner et al., 2003b; Yang et al., 2003). 
IGF-2 significance and loss of imprinting : IGF-2 is a secreted growth hormone used 
predominantly in mammalian embryos to achieve exponential growth in tissue and size. IGF-2 
along with IGF-1 (Insulin like growth factor-1), Insulin, their cognate receptors IGF-1R and Insulin 
receptor (IR) and six high-affinity binding proteins form a closely related signaling axis that 
regulate important cellular processes like survival, proliferation, metabolism and cellular 
differentiation amongst many other (Baserga et al., 1997). Although the IGF-2 expression is 
tightly regulated in tissues by epigenetic imprinting, the imprinting can be lost spontaneously in 
a tissue specific manner referred to as the Loss of Imprinting  (LOI) of IGF-2. LOI of IGF-2 in the 
colon, leading to an approximately 2-fold increase in expression, results in abnormally elongated 
crypts in the colonic mucosa accompanied by a 5 fold increase in the probability of colorectal 
adenocarcinoma when compared with the general population (Sakatani et al., 2005). Similarly in 




common forms of bone cancer. Also, LOI of IGF-2 in the kidney and peripheral blood leukocytes 
is accompanied by increased somatic overgrowth (gigantism) and increased predisposition to 
Wilms’ tumor, a nephroblastoma seen in children (Ogawa et al., 1993). Thus the regulation and 
maintenance of imprinting of IGF-2 is an increasingly important factor for normal homeostasis in 
cells and tissue. 
IGF-1R signaling : IGF-2 signals through the IGF-1R, a classic growth factor receptor tyrosine 
kinase, causing the phosphorylation and activation of the two downstream kinases Akt and Erk. 
IGF-1R and Insulin receptor (IR) share extensive (approx. 70%) sequence and structural 
homology and are remarkably similar in their size and exon organization (Ullrich et al., 1986). 
Both IGF-1R and IR are synthesized as single pro-receptor with a 30 aminoacid signal peptide 
that is removed during translocation. The modified and glycosylated pro-receptor is cleaved at a 
Arg-Lys-Arg-Arg site to generate an alpha and a beta sub-unit. These alpha and beta sub-units 
are linked via di-sulphide bonds to assemble the functional IGF-1R which is a hetero-tertramer 
composed of two alpha and two beta sub-units respectively. The alpha sub-units are fully 
extracellular while the beta units span the membrane and contain the cytoplasmic tyrosine 
kinase signaling domain (Ward and Garrett, 2004). IGF-1R can also form hetero-tetramers with 
IR isoforms. IR has two isoform, IR-B and IR-A. IR-B is predominantly expressed in the muscle, 
adipose tissue and the liver and is used in the regulation of glucose uptake while IR-A which is 
usually expressed in embryonic tissue and in certain tumors has great affinity for binding IGF-2 
(Sciacca et al., 2002). The IGF-2R on the other hand is a generic Mannose-6-phosphate receptor 
and lacks the intrinsic cytoplasmic kinase activity of the IGF-1R.  The IGF-2R acts to bind, 
sequester and degrade IGF-2 (Nolan et al., 1990). 
On binding its ligand, IGF-1R undergoes a conformational change and autophosphorylates the 
tyrosines Y1131, Y1135 and Y1136 on its cytoplasmic tail. The tyrosine residues Y1131, Y1135 
and Y1136 form the important activation loop, the tyrosine Y950 serves as a docking site for 
important signaling molecules and the lysine K1003 binds ATP (Baserga, 2005). The 
phosphorylated tyrosines recruit adaptor molecules like IRS-1 and activate Akt via the PI3k 
pathway (Baserga et al., 1997; Pollak, 2012). The phosphorylated IGF-1R also recruits factors like 
Shc, Grb2 and Sos and activates Erk via Ras and the MAPK pathway (Baserga et al., 1997; Peruzzi 
et al., 1999; Pollak, 2012). Akt, a ser/thr kinase, plays a central role in glucose metabolism, 
transcription, translation, apoptosis and survival signaling, cellular proliferation, differentiation 
and migration. Erk, which is also a ser/thr kinase, plays an important role in proliferation, cell 
cycling and differentiation. Activated Erk translocates into the nucleus and activates a host of 
transcription factors that regulate many cellular processes. Although both Akt and Erk are 
downstream effectors of the IGF-1R, their relative strengths can be affected by many of the 
adaptor complexes and processes that can independently regulate the kinases. In smooth 
muscle cell culture, a shift in the balance of signaling from PI3k to Erk signaling induced by 
different growth factor receptors can cause the cells to de-differentiate (Hayashi et al., 1999).  




cell-fate decision in response to NGF (Chen et al., 2012). Thus IGF-2, acting through the IGF-1R 
can cause differential fates in cells depending on the Akt, Erk signaling strength. 
Receptor trafficking : The signaling activity of IGF-1R and other growth factor receptors in 
general are regulated by endocytosis and intracellular trafficking (Burke et al., 2001). Activated 
receptors are clustered into pits (small invaginations in the cell membrane) and internalized 
rapidly into these clathrin coated pits (Ramanan et al., 2011). These pits then pinch off from the 
membrane and form vesicles that the receptors continue signaling from. These vesicles can then 
either fuse with vesicles coming out of the transgolgi and recycle back to the membrane or be 
targeted to the lysosomes for degradation(Sorkin and Goh, 2009). Receptors that are targeted 
to the lysosomes for degradation have been known to not bind the ligand anymore and not be 
in an active state of signaling (Burke et al., 2001). Thus an emerging theme in vesicular 
trafficking is the modulation of receptor signaling via compartmentalization into vesicles and 
their trafficking. 
In addition to the elements of the endocytic and vesicular trafficking machinery, other known 
adaptor molecules have known to play a role in modulating activated receptor signaling in the 
context of Erk and Akt signaling. β-Arrestin 1 and 2 are proteins that play a major role in the 
desensitization of GPCR / 7 transmembrane receptors signaling. They have been shown to  not 
only play an important role as an endocytic adaptor but to behave as scaffolding structures for 
the activation of MAP kinases like Erk1/2 and other pathways (Girnita et al., 2007). In fact the β-
Arrestin 1 mediated Erk activation was shown to be independent of the second messenger when 
the classical receptor tyrosine kinase activity is impaired. Another class of molecules that are 
known to play an important role in receptor signaling are E3 ubiquitin ligases like Mdm2, Nedd4 
and c-Cbl. Mdm2 is the regulator of the tumor suppressor protein p53. Mdm2 ubiquitinates p53 
and is also known to actively shuttle between the nucleus and cytoplasm controlling the levels 
of p53. Mdm2 was shown to be involved in ubiquitinating IGF-1R and thus behaving as a E3 
ligase (Girnita et al., 2003). Similarly another ubiquitin ligase Nedd4 was shown to associate with 
IGF-1R and in a dose dependent manner increase the ubiquitination of IGF-1R when stimulated 
with IGF-1 in mouse embryonic fibroblasts (Vecchione et al., 2003). Recently it was shown that 
another E3 ubiquitin ligase associated with EGFR signaling, c-Cbl, on ligand stimulation with IGF-
1, associated with IGF-1R and polyubiquitinated it. Interestingly it was shown there that Mdm2 
associated with IGF-1R at lower doses of IGF-1 while c-Cbl associated with IGF-1R for higher 
doses of IGF-1. It was also shown that while Mdm2 mediated ubiquitination resulted in a 
clathrin coated endocytic route for IGF-1R, the c-Cbl mediated ubiquitination resulted in a 
caveolin mediated endocytic route (Sehat et al., 2008). Thus both adaptor molecules like β-
Arrestins and E3 ubiquitin ligases can play an important role in receptor signaling and Erk 
activation. 
Computational models of Erk and Akt signaling : Given the importance of Erk and Akt signaling 
in cellular homeostasis, the dynamic nature of the Akt, Erk response to different ligands in 
different growth factor systems, the diverse nature of cellular fates dictated by transient vs 




their activation, these two pathways have been modeled computationally in many different 
systems. Although there aren’t many examples of computational models of IGF-1R signaling in 
literature, models of Akt and Erk signaling activated via growth factor receptors should prove 
instructive. A computational model of Heregulin induced Erb receptor (EGFR) activation leading 
to Akt and  Erk signaling suggested substantial cross-talk between the Akt and Erk pathway via 
PI3k and its phosphorylation of the Ser-259 residue on Raf-1. The model also strongly suggested 
the modulation of the activity of members of the Akt and Erk pathway by the phosphatase 
PP2A. In the model, activated receptor-complexes activated PI3k which then activated Akt. The 
receptor complexes also phosphorylated Shc which then recruited adaptors Grb2, Sos thereby 
activated Ras. Ras activation initiates the MAPK cascade by activating Raf-1 which also cross-
talks with the MAPK pathway (Hatakeyama et al., 2003).  Other models of the Akt and Erk 
pathway include a study that focused on the cross-regulation of EGF and Insulin signaling in 
HEK293 cells. The model was used to study the effect of Insulin on Erk signaling which is minimal 
on its own but gets amplified in the presence of very low doses of EGF. The model revealed 
certain cross-talk mechanisms upstream of Ras and the importance of the critical nodes like 
Gab1, Shc, IRS-1, Src Kinase, Shp2 phosphatase in amplifying the PIP3 signals that are converted 
to enhanced Erk activity (Borisov et al., 2009) 
Oncogene / IGF-2 addiction : In an in-vivo colon tumor model for IGF-2 LOI, it was seen that the 
mice displayed an enhanced responsiveness to a drug targeting the IGF-1R kinase function. The 
mouse model carried a deletion in the H19 gene and an additional 10 kb of the upstream region 
including the differentially methylated region (DMR) thus regulating the silencing of IGF-2. 
When treated with Azoxymethane (AOM), the animals formed an increased number of aberrant 
crypt foci (ACF) in the colon when compared to matched WT (LOI negative) mice. Subsequent 
treatment with NVPAEW541 a potent inhibitor of the IGF-1R kinase triggered a significant 
decrease in the number of ACF in LOI mice, while the WT mice showed no change in the number 
of ACF. Oncogene addiction is a term used in cancer literature to describe the increased 
dependence of a particular cancer on the oncogene driving it. Such cancer cells are also shown 
to be increasingly sensitive to inhibition of the oncogene (Sharma and Settleman, 2007). Some 
of the common driver genes seen in oncogene addiction include Myc, Ras proteins, Epidermal 
growth factor receptor (EGFR), Platelet derived growth factor receptor (PDGFR), Phosphatase 
and tensin homologue (PTEN) etc. (Weinstein and Joe, 2008). Thus, the IGF-2 LOI animal model 
shows an increased dependence on IGF-2 signaling reminiscent of oncogene addiction in 
cancers. 
Colon crypt modeling :  Tissue renewal is one of the most important aspects of systemic 
homeostasis. Organs like the intestine, blood, skin etc undergo various stages of massive 
renewal throughout the day in a living multicellular organism, such that the cycle of losing cells 
that perform the function of the organ to various environmental challenges is intricately 
balanced by the renewal of the organ such that the organ maintains its size and functional 
organization throughout its life (Frank, 2007). . A considerable majority of the organs employ the 




relatively slowly proliferating stem cells (Bach et al., 2000; Ghazizadeh and Taichman, 2001; 
Potten and Booth, 2002) ensure genomic integrity and form an indefatigable, replenishable 
source of more functional differentiated cells. As dictated by the architecture of the organ and 
the needs of the organ, dividing stem cells can, with defined probabilities, either self-renew or 
differentiate into transit amplifying cells, which no longer have the stem cell property. These 
transit amplifying cells then rapidly proliferate, make up the core of the structure of the organ 
and after a certain number of cycles, fully differentiate into the functional cells of the organ.  
Needless to say, the stem cells, by virtue of their unlimited capacity for cell division, dictate the 
dynamics of the cell numbers in the crypt. In summary, given the need to maintain genomic 
integrity and geometrically defined structure of self-renewing organs, stem cells divide 
infrequently and also employ both symmetric and asymmetric cell divisions to perform the dual 
nature of maintenance of the stem cell pool and the required number of progeny to 
differentiate and perform the functional roles of the organ (Morrison and Kimble, 2006; Watt 
and Hogan, 2000) 
The crypts in the colon are perhaps the most well characterized and studied examples of 
epithelial tissue renewal system. Colonic crypts are minute finger like invaginations in the 
colonic epithelium that are composed of a single layer of cells and are shaped in the form of a 
test tube (Simons and Clevers, 2011). The crypts provide a continuous stream of cells mainly 
enterocytes and goblet cells to the colonic epithelium and are responsible for replenishing the 
same as they slough off into the lumen of the colon. The crypt is organized into a small pool of 
stem cells at the bottom (Barker et al., 2007; Bjerknes and Cheng, 2002), a large pool of rapidly 
proliferating cells along the length of the crypt which constitute the transit-amplifying pool and 
a pool of fully differentiated non-proliferating cells along the upper third of the length of the 
crypt. As the self-renewing  stem cells divide, the newly formed daughter cells advance up along 
the length of the crypt and partially differentiate into the cells of the transit amplifying 
compartment. These partially differentiated cells in the transit amplifying compartment 
proliferate rapidly and are responsible for supplying differentiated cells to the colonic 
epithelium at the rate at which they are lost into the lumen of the colon. As the cells in the 
transit amplifying compartment rise up the length of the colon they stop proliferating, acquire 
very differentiated phenotypes and become the functional cells of the colonic epithelium 
(Simons and Clevers, 2011). IGF-2 LOI in the colon alters the balance between undifferentiated 
and differentiated cells along the length of the crypt. This is also accompanied by an increase in 
the average length of the crypts. 
Noise is inherent in all biological systems, most often manifesting itself as stochasticity in 
measured responses and observed values of system variables. The stochasticity can be a 
function of many known and unknown processes and serves to impart useful properties to the 
system like robustness, variability, ability to recover from crippling errors and such (Wang and 
Zhang, 2011). In terms of the colonic crypt, there is inbuilt stochasticity in almost every aspect of 
the dynamics and organization of the crypt i.e., in the density of the number of crypts per unit 




crypt, in the total number of cells in each crypt, in the number of stem cells, number of transit 
amplifying cells, in the cell cycle time of cells in the different compartments, effectively from the 
tissue level organization to the cellular details of cell cycling and proliferation (Boman et al., 
2008).  
Many attempts have been made to develop mathematical models to understand the 
homeostasis and aberrant behavior, in the case of cancer, of the colonic crypts(Gerike et al., 
1998) (Buske et al., 2011; Johnston et al., 2007). Most of the models that have been recently 
developed are deterministic in nature in that cell cycle analysis, number of stem cells etc are 
defined by ordinary differential equations (Boman et al., 2008). Although they have been used in 
other population based systems truly stochastic models have not really been used to describe 
the behavior of tissue renewal or in this case crypt organization and homeostasis. Stochastic 
models have the advantage of being able to model the colonic crypt in its true form and account 
for the noise, randomness and inherent variability that are evident when repeated 
measurements are made of the crypt parameters. They also have the added advantage that the 
average behavior of system parameters predicted by the stochastic models will correspond to 
the values predicted by the deterministic models. 
Renewal process is a stochastic random process that is a generalization of the Poisson process 
(Cox, 1970). It is a counting process on the space of integers and is defined by the time intervals 
between the occurrence of events and the probabilities of the counting at each such event 
occurrence. A renewal reward process can be defined on the same renewal process with the 
incremental changes in the renewal process constituting the counting process (Cox, 1970). As 
the main events that occur in the stem cell pool are the spontaneous mitosis of the cells into 
two daughter cells and the probabilistic event of those cells choosing to either stay as stem cells 
or differentiate (Boman et al., 2007), it is quite easy to note the similarity between the events in 
the stem cell pool and the renewal process.  Furthermore, the main function of the process, 
formation of appropriate numbers of differentiated functional cells, can be seen as a reward. 
We can then attempt to model the number of cells in the stem cell pool as a renewal process 
and the process of differentiation whereby these cells lose their stem cell properties and 
become the transit amplifying cells as a renewal reward process.   
In addition to the simplicity of representation and the inherent stochasticity associated it, both 
features being very useful when dealing with stem cell differentiation process, the use of 
renewal theory enables us to take advantage of the vast number of results and theorems 
developed independently of description of biological processes. As shown below, by using the 
fundamental theorem of renewal-reward process, for example, we can quite easily derive an 
equation for the average rate of cells differentiating and exiting the stem cell pool in terms of 
other parameters that define the stem cell pool. We then use this result to test the validity of a 







Chapter  1 : Re-balance in the IGF-2 signaling network 
 
A previous analysis from our lab and our collaborator’s (Kaneda et al., 2007) suggested that 
there might be important differences in the kinetics of activation of canonical signaling 
pathways stimulated by IGF-2. Re-examination of the kinetic activation profiles of the two 
dominant pathways activating the kinases Akt and Erk1/2, surprisingly suggested that, although 
both these pathways are activated by the same ligand, their maximal activities change in 
divergent directions in LOI cells vs. WT cells (Fig. 1.1A, 1.1B). More specifically, when stimulated 
with 100ng/ml of IGF-2, the activity of Akt was significantly attenuated and the activity of Erk -- 
enhanced in LOI cells vs. WT cells. This result was seen for both the peak values of the temporal 
activity profiles (Fig 1.1A inset) and for the signaling activities integrated over 3 hr. time period 
(Supplementary Fig S1). The results of this immunoblot analysis were supported by 
immunocytochemistry experiments performed on population of single cells (Supplementary Fig 
S2). The results raised several questions: 1) what is the mechanism of the differential regulation 
of two pathways, both of which are activated by the same receptor-ligand complex? ;  2) is this 
mechanism related to the differential expression of the IGF-2 receptor IGF-1R displayed by LOI 
cells (Kaneda et al., 2007); 3) is the differential change in the pathway activities in LOI vs. WT 
cells connected to the increased proliferation and elevated sensitivity to IGF-1R kinase inhibition 
displayed by LOI cells? The following analysis set out to answer these questions. 
Although activation of growth factor receptors can lead to enhanced activities of both Erk and 
Akt pathways (Lemmon and Schlessinger, 2010; Siddle, 2011), the intracellular signaling 
compartments supporting these pathways are distinct (Jullien et al., 2002) (Vieira et al., 1996). 
Indeed, prior studies suggested that the Akt pathway is preferentially activated at the plasma 
membrane, whereas the Erk pathway -- in the internalized vesicles (Biedi et al., 2003) (Chow et 
al., 1998) (Vasilcanu et al., 2008). Therefore receptor internalization or recycling can increase 
the propensity for activation of one of the branches of the signaling network at the expense of 
the other (Holbrook et al., 1999) (Sorkin and von Zastrow, 2009) (Tan et al., 2013) thus 
rebalancing the pathway activities within the signaling network (Chen et al., 2012) (Lu et al., 
2011; Ren et al., 2010; Worster et al., 2012) The increased accumulation of IGF-2 in the vicinity 
of LOI cells associated with doubling of the copy of the active IGF-2 can increase signal mediated 
receptor internalization, creating potential for network rebalancing (Clemmons, 2007). We 
indeed observed significant ligand-induced internalization and concomitant degradation of IGF-
1R over 3 hrs. in LOI but not WT cells (Fig. 1.2A, B and Fig 1.3). Receptor degradation was 
completely abrogated by inhibitors of lysosomal (Chloroquine) and proteasomal (MG132) 
degradation (Fig. 1.2A). Surprisingly, longer term stimulation of LOI but not WT cells also 
revealed an increase in transcriptional regulation of IGF-1R (Fig. 1.4). These results suggested 
that both the amount and the localization of the IGF-1R can be controlled by IGF-2 mediated 






Exponentially growing LOI and WT cells were serum starved overnight and stimulated with IGF-2 100ng/ml for the 
indicated time points, harvested and analyzed by Western blotting.  A) The pAkt profiles for both LOI and WT cells 
peak at 10 minutes and adapts to a steady state value while the pErk profiles for both WT and LOI cells peak at 10 
minutes and then returns to basal levels by 30 min. LOI cells show a much stronger pErk stimulation as opposed to a 
much weaker pAkt stimulation when compared to WT cells (Inset: Peak values at t=10 min, Student’s t test with N=3 ) 
B) Re-balancing of the IGF-2 signaling network.   





Figure 1.2 :  Ligand induced short term receptor degradation :  
A,B)  LOI and WT cells were serum starved overnight, stimulated with IGF-2 (100ng/ml) for the indicated time points, 
harvested at the end of it and analysed by Western blotting  after normalizing every band by value t=0. The same 
experiment was repeated with inhibitors of lysosomal (Clq) and proteasomal (Mg132) degradation and plotted in 
black. Statistics used – student’s t test with N=3. 
 
Does the receptor internalization affect Erk and Akt signaling (alt. does it lead to 'rebalancing of 
the network'?) A small molecule inhibitor of receptor endocytosis Monodansylcadaverine (MDC) 
(McMahon and Boucrot, 2011; Schutze et al., 1999) completely abolished Erk signaling in LOI 
cells (Fig. 1.5A). On the other hand, the Akt signaling, although mildly attenuated, occurred with 
similar dynamics in the absence of the receptor internalization (Fig. 1.5B).  This result supported 
the importance of receptor trafficking in differential stimulation of the branches of the signaling 
network, but also raised the question of what might account for adaptation of Akt activity in the 







Figure 1.3 : Rate of receptor internalization  
Cell surface receptors of LOI and WT cells were biotinylated with NHS-biotin on ice, treated with IGF-2(100ng/ml) and 
allowed to internalize at 37degC for the indicated times and then harvested after the remaining surface biotin was 
cleaved. The internalized Biotin was pulled down with Streptavidin beads and analyzed by Western blotting. 
 
 
Figure 1.4 : Ligand induced long term receptor transcription  
LOI and WT cells were serum starved overnight, stimulated with IGF-2(100ng/ml) for the indicated time points, 
harvested  and analysed by qRT-PCR. IGF1R expression was normalized against β-Actin in each well and further 






Figure 1.5 :  Internalization of receptors regulates Erk activation :  
LOI cells were serum starved overnight and treated with either 100µM MDC (Monodansylcadaverine) for 1 hour 
followed by IGF-2 or just IGF-2 for the indicated timepoints, harvested and analysed by Western blotting. A) 






Figure 1.6 : Akt dynamics is driven by receptor degradation, recycling and cell surface phosphatases  
Exponentially growing LOI cells were serum starved overnight and treated with either Monensin Sodium (recycling 
inhibitor) or a combination of Mg132(proteasomal inhibitor) + Chloroquine(lysosomal inhibitor) or a combination of 
all the three for 60 minutes followed by IGF-2 stimulation for 10 minutes, harvested and analyzed by Western 
blotting. C) Receptor recycling to the surface and receptor degradation cause the adaptation of pAkt levels from their 
peak values to a steady state value. As in the previous experiment cells were treated with Okadoic Acid (OKA - 
inhibitor of the cell surface pAkt phospatase -PP2A) instead of Monensin and analyzed via Western blotting. D) It can 
be seen that by inhibiting the cell surface Akt phosphatases and receptor degradation the same result can be 





active receptors due to receptor degradation (Fig. 1.2A) (Girnita et al., 2003), other aspects of 
receptor trafficking and phosphatase activity at the plasma membrane. To explore these 
possibilities, we first used the cocktail of inhibitors of receptor degradation (MG132 + 
Chloroquine) and vesicle recycling (Monensin) (Marnell et al., 1982). This cocktail completely 
abolished the adaptation in Akt response (Fig. 1.5 A), whereas either the inhibitor of 
degradation or inhibitor of recycling alone failed to do so (Fig. 1.5A). The effect of the cocktail 
was replicated when Okadaic acid -- an inhibitor of cell surface phosphatase PP2A (Liu et al., 
2003) was used instead of Monensin (Fig. 1.6A). Okadaic Acid or the receptor degradation 
inhibitors used separately failed to abrogate the Akt adaptation (Fig. 1.6B). These results, in 
combination, suggested that an increased receptor internalization in LOI cells can indeed lead to 
preferential activation of Erk, with the activity of Akt regulated at the plasma membrane by both 
the availability of the receptors and the action of the plasma membrane localized PP2A.  
The observation of a long term increase in IGF-1R transcription and preferential activation of the 
Erk pathway in IGF-2 stimulated LOI cells suggested that Erk might influence IGF-1R expression 
in a feedback fashion. Indeed, we found that a Mek inhibitor U0126, which abolishes Erk 
signaling, abrogated the increase in the IGF-1R mRNA levels, after LOI cell stimulation with IGF-2 
over a period of 24 hours (Fig. 1.7). Interestingly, when analyzed over a shorter term (15 min.), 
LOI cells pre-treated with U0126 and stimulated with IGF-2 showed a significant increase in IGF-
1R protein levels (Fig. 1.8). This result suggested that the Erk pathway might also control the 
short term receptor degradation following IGF-2 mediated cell stimulation.  Indeed, we 
observed that, in the presence of a proteasomal inhibitor MG-132 used to prevent the 
degradation of ubiquitinated proteins and to enhance their detection, the Mek inhibitor U0126 
decreased ubiquitination of IGF-1R (Fig. 1.9). Since it was shown previously that ubiquitination 
of IGF1R is a necessary step for its internalization (Sehat et al., 2007), these results suggest that 




receptor internalization and degradation, and a longer term receptor synthesis. 
 
Figure 1.7 : Erk signaling mediates long-term IGF1R transcription  
LOI cells were serum starved overnight and treated with the Mek inhibitor U0126 (or no inhibitor in the case of 
positive control) for 60 minutes, stimulated with IGF-2 for the timepoints indicated and analysed by qRT-PCR for 
IGF1R expression.  The IGF1R expression in each well was normalized to the β-Actin and plotted as fold expression 
over value at t=0.  Use of the Mek inhibitor abolishes the Erk mediated IGF1R long-term transcription seen in LOI cells. 
Statistics used, student’s t test with N=3 
 
Figure 1.8 : Erk signaling mediates IGF1R degradation  
LOI and WT cells were serum starved overnight and treated with the Mek inhibitor U0126 (or no inhibitor in the case 
of positive control) for 60 minutes, stimulated with IGF-2 for 10 minutes, harvested in lysates and analysed by 
Western blotting. Increased IGF1R levels in LOI cells show an Erk mediated short-term degradation while the IGF1R 






Figure 1.9 : Erk mediates IGF1R ubiquitination  
LOI cells were serum starved overnight and treated with MG132 (proteasomal inhibitor), U0126 (Mek inhibitor) or no 
U0126 for  control, IGF-2 for 10 minutes, harvested in lysates and immunoprecipitated with anti-IGF1R antibodies. 
The samples were then analyzed by immunoblotting with anti-Ubiquitin and anti-IGF1R antibodies.  Mek inhibitor 
decreases / abolishes the Erk mediated IGF1R ubiquitination driven by IGF-2 stimulation. 
 
The results above thus suggested that a feedback loop may exist in LOI cells, in which the Erk 
pathway can enhance its own signaling activity by increasing internalization and synthesis of 
IGF-1R. This positive feedback might help explain elevated levels of expression of this receptor 
found in LOI cells and enhanced Erk-dependent proliferation of these cells. To explore this 
possibility further, we developed a computational model of the IGF-2-IGF-1R-Akt-Erk signaling 
network (Fig. 1.10), which we trained on the experimental datasets shown in symbols in the left 
hand panels of Figs 1.11 (also in Fig. 1.1A). The model prediction for the dynamics of the WT cell 
responses, simulated under the assumption that these cells were only different from LOI cells in 
terms of the receptor expression and rate of its internalization, qualitatively matched the 
experimental data (in blue, top and bottom right panels Fig. 1.12). The computational model 
further predicted that the Erk mediated positive feedback impinging on receptor regulation 
could lead to a sustained increase in both receptor expression and Erk signaling, usually 
associated with the LOI phenotype. This result suggested that the enhanced expression of the 
IGF-2 ligand can ultimately trigger a new state of the cell, characterized by an enhanced Erk 








Figure 1.10 :  Systems model for IGF-2 signaling  








Figure 1.11 : Training, testing and prediction :  
The model was trained on 3 sets of experimental data used before to obtain the pAkt and pErk profiles of LOI cells 
stimulated with IGF-2 cells. 3 sets of parameters of the model were estimated based on the 3 sets of data and the 
corresponding model fits are shown in the left panels. The 3 sets of parameters estimated from the data were then 
averaged to obtain the trained mean set of parameters. This model was then used to predict the average pAkt and 
pErk response of the LOI cells to IGF-2 as shown in red in the panels on the right. The number of IGF1R, IGF1R:IR and 
the internalization rate of the model were changed to stimulate WT behavior and the model prediction for pAkt and 













Figure 1.12 :  Positive feedback and thresholding effect :  
The Erk mediated positive  feedback on IGF1R can be used to explain the difference in LOI and WT cells and postulate 
the presence of a threshold. The Erk integration is plotted for values of IGF-2 and the IGF1R transcriptional feedback 
















Chapter 2 : Propagation of network re-balance and physiological 
implications 
 
What are the consequences of altered balancing of the Erk and Akt signaling pathway activities 
in LOI vs. WT cells, particularly in regulation of cell survival when challenged with the IGF-1R 
kinase inhibitors? Both of these signaling pathways have the potential to control cell 
proliferation and survival, in part through regulation of the balance of abundance of pro- and 
anti-apoptotic Bcl family proteins (Kennedy et al., 1997) (Scheid et al., 1999). We indeed found 
that Bax, a pro-apoptotic member of the Bcl family, was overexpressed in LOI cells vs. WT cells 
following IGF-2 stimulation (Fig. 2.1A). Conversely, Bcl-2, an anti-apoptotic member of the Bcl 
family was expressed at lower levels in LOI cells under the same conditions (Fig. 2.1B). 
 
 
Figure 2.1 : Bax and Bcl-2 show altered balance in LOI and WT cells .  
Exponentially growing WT and LOI cells were serum starved overnight and stimulated with 10%FBS for 24 hours, 
harvested in lysates and analyzed by Western blotting for A)pro-apoptotic Bax and B)anti-apoptotic Bcl-2. Student’s t 
test was used with N=3 
 
 The change in the balancing between Bax and Bcl-2 in WT vs. LOI cells was confirmed in 
individual cells double-stained using antibodies against these proteins (Fig. 2.2). Examination of 
expression of other members of the Bcl-2 protein family suggested the roles of other pro and 
anti – apoptotic proteins like Bak-1 and Bcl-Xl, although their levels were not significantly 
different between WT and LOI cells (Fig. 2.3). To explore a possible relationship with differential 




affected by the perturbation of the IGF-2 stimulated signaling activities. We found that LOI cells 
pre-treated with the Mek inhibitor U0126 at various doses followed by IGF-2 stimulation for 24  
 
Figure 2.2 : Bax, Bcl-2 joint distribution:  
WT and LOI cells were co-stained for Bax and Bcl-2 and analyzed by immunofluorescence.  The mean intensity in each 
cell was computed and plotted as a 2d-histogram. The Bax, Bcl-2 marginal distributions are also computed and 







Figure 2.3 :  Anti/Pro- apoptotic panel :  
Exponentially growing LOI and WT cells were analyzed by qRT-PCR for 4 anti/pro-apoptotic proteins of the Bcl family. 
The expression of mRNA transcripts was plotted after normalizing to β-Actin values in the same well. 
 
 
Figure 2.4 : Erk regulates Bax not Bcl-2  
LOI cells were serum starved overnight and then treated with varying concentrations of U0126 (Mek inhibitor) for 60 
min followed by IGF-2 for 24 hours. The cells were harvested and analyzed via Western blotting for A) Bax and B) Bcl-
2. Student’s t test with N=3 was used. 
 
hours showed a dose dependent response of Bax protein levels (Fig 2.4A), but also interestingly 
in those of c-Myc (Supplementary Fig. S). On the other hand Bcl-2 levels were not affected by 




on Bcl-2 (Fig 2.4B). Similarly, the expression of Bcl-2 showed dose-dependent sensitivity to a 
PI3K inhibitor LY294002 following similar IGF-2 stimulation (Supplementary Fig.S9). These results 
suggested that both canonical IGF-2 activated signaling pathways can indeed impinge on 
regulation of pro- and anti-apoptotic processes, through regulation of the Bcl family proteins.  
To provide quantitative support for this hypothesis, we expanded the computational model 
using a simple assumption, postulating that the abundance of Bax and Bcl-2 is a function of Erk 
and Akt activities respectively integrated over time (Fig. 2.5). Using this assumption (see Supp. 
Materials for other details on the model expansion) we could predict the relative abundances of 
Bax and Bcl-2 proteins in LOI and WT (Lindner et al., 2013; Raychaudhuri and Das, 2013) (Fig. 
2.5). In combination, these results provided support for the hypothesis that re-balancing of 
signaling pathways in the IGF-2 stimulated signaling network can lead to further re-balancing of 
Bcl family proteins leading to differential propensity of LOI and WT cells to undergo apoptosis. 
We provide further evidence for this hypothesis. 
 
 
Figure 2.5 : Computational model extension for Bax, Bcl-2 signaling :  
The IGF-2 computational signaling model was extended to include Bax, Bcl-2 signaling downstream of Akt-Erk 
signaling. The Akt and Erk signals are integrated to obtain Bax and Bcl-2 signals. 
 






Chapter 3 : Increased sensitivity of LOI cells to IGF-1R kinase 
inhibition. 
 
The re-balance of Bcl-2 and Bax can lead to differential sensitivity of LOI vs. WT cells to agents 
affecting the components of the signaling network (Oltvai et al., 1993; Perlman et al., 1999). 
Indeed, our prior observations suggested that LOI but not WT cells are highly sensitive to 
inhibition of the IGF-1R kinase activity by NVPAEW-541 (Kaneda et al., 2007). NVPAEW-541 was 
preferentially found to de-activate Akt while having a much milder effect on Erk (Fig. 3.1). 
 
 
Figure 3.1 NVPAEW541 abolishes Akt signaling selectively  
WT and LOI cells were serum starved overnight and treated with indicated doses of NVPAEW541 for 60 minutes 
followed by IGF-2 for 10min. The cells were harvested in a lysate and analyzed by Western blotting. Both LOI and WT 
cells show an attenuated Erk signaling while the Akt signaling is completely abolished. 
 We therefore explored computationally whether the expanded model of the signaling network 
would predict higher sensitivity of LOI cells vs. WT cells to the inhibition of the IGF-1R kinase. 
Indeed, the model predicted that a given level of IGF1R  inhibition can lead to distinct levels of 
Akt activity in these cells and, as a consequence, allow for greater ‘domain’ of tolerance to the 
perturbation under which Bcl-2 levels would still exceed the levels of Bax (Fig. 3.2). Since the 
relative excess of Bax vs. Bcl-2 (or vice versa) is thought to lead to the pro-apoptotic (vs. anti-
apoptotic response) response, this result suggested that a much greater dose of the kinase 





Figure 3.2 : : Increased susceptibility to Bcl-2 inhibition  
Simulated Bax, Bcl-2 distributions for LOI and WT cells were plotted based on [Bcl-2] > [Bax] for survival. [Bcl-2]=[Bax] 
line separates the survival region from the apoptosis region. The centroids for the Bax, Bcl-2 distributions of WT and 
LOI cells are marked and the distances of the centroids from the [Bcl-2]=[Bax] line is also shown. 
 
We first quantified this prediction by taking into account variability in the levels of Bax and Bcl-2 
expression in the LOI and WT cell populations (Fig. 3.3B). Given this variability we could predict 
the % survival of the cellular population following exposure to various doses of NVPAEW-541 
using the Bcl-Akt derived relationship from the computational model (Fig. Fig. 3.3A). The results 
yielded good match with the experimental analysis, providing additional support for model 
assumptions and for the proposed mechanism for the differential sensitivity by LOI and WT cells 
to IGF1R kinase inhibitor (Fig. 3.3C and Fig 3.3D) 
The stoichiometric imbalance of Bax and Bcl-2 can trigger apoptosis through the instrinsic 
mitochondrial apoptotic pathway. This results in activation of the Caspases pathway, particularly 
the initiator Caspase-9 and the effector Caspase-3 (Kluck et al., 1997). The activities of both 
Caspases-9 and -3 were dramatically upregulated in LOI vs. WT cells within a few hours following 
exposure to NVPAEW-541 (Fig. 3.4A and 3.4B), consistent with many instances of increased 
upregulated (activated) Bax expression levels in these cells at these earlier time points of 5 hrs. 
following the stimulation with the drug (Fig. 3.4C). Annexin-V staining provided further support 
for regulated cell death in LOI cells (Supplementary Fig S). Overall, these results were consistent 
with the apoptotic regulation of cell death in LOI cells treated with the IGF-IR kinase inhibitor, 






Figure 3.3 : Enhanced sensitivity of LOI cells to Akt inhibition  
Using the IGF-2 signaling model a mapping from Akt inhibition to Bcl-2 inhibition was computed and plotted. Akt 
signaling was inhibited according to the percentages shown on the x-axis and the corresponding Bcl-2 levels were 
plotted on the y-axis. C) Bax, Bcl-2 distributions were generated with means corresponding to the centroids of the 
Bax, Bcl-2 distributions as shown in panel A) and using the standard deviations computed from the doubly-stained 
joint distributions measured and shown in Fig 4F. D) Based on the number of cells alive as dictated by [Bcl-2]>=[Bax], 
the percentage of Bcl-2 inhibition was plotted against the percentage of cell survival for WT and LOI cells. Survival 
curves E) WT and LOI cells were serum starved overnight and treated with indicated doses of IGF1R kinase inhibitor 
NVPAEW541 for 24 hours, analyzed for cell survival by Alamar blue dye. The survival is plotted as a percentage of the 






Figure 3.4 : Activated Caspase-9, Caspase-3 and Bax 
A) WT and LOI cells were serum starved and treated with 5µM NVPAEW541 for the indicated time points, harvested 
in lysates and analyzed by Western Blotting for activated Caspase-9 and Caspase-3. Both the early Caspase-9 and the 
effector Caspase-3 are seen to activated by t=5 hours in LOI cells while no activation is seen in WT cells. B) The 
Caspase-9 and Caspase-3 activation was measured by using substrates with Caspase cleavage site conjugated to 
fluorophores in both LOI and WT cells. Caspase activation produced a fluorescent signal proportional to the Caspase 
activity. C) LOI cells were serum starved overnight and treated with either IGF-2 or 5uM NVPAEW541 for 5 hours, 
fixed on coverslips and analyzed by immunofluorescence for antibodies specific to activated Bax. Bax activation as 




Chapter 4 : IGF-1 response 
 
The results presented so far provide evidence for the hypothesis that LOI cells, by virtue of 
increased expression of IGF-2, can enter a new state characterized by both an enhanced 
proliferation and higher propensity to undergo apoptosis, with the latter effect particularly 
pronounced if IGF-1R and Akt activities are suppressed. However, it is not clear, if re-balancing 
of the signaling network is specific to IGF-2, or can potentially be mimicked by an increase of 
other ligands capable of binding to IGF-1R, including IGF-1. This question can also be expanded 
to include the notion that IGF-I and IGF-II bind to IGF1R homo-dimers or IGF1R-Insulin Receptor 
(IR) heterodimers with different affinities.  We found that the propensities to form the receptor 
homo- and hetero-dimers varied between LOI and WT cells, with LOI cells displaying both higher 
levels of receptors and higher relative occurrence of  IGF1R homodimers (Fig. 4.1A). Since IGF-1 
preferentially binds to IGF-1R homodimers, the assumptions of the IGF-2 triggered network 
activity used in our prior analysis were unchanged. However, since IGF-I has altered specificity of 
binding to both homo- and hetero-dimers of IGF-1R, we examined computationally and 
experimentally, how the activities of the signaling pathways within LOI and WT cells would 
respond to this ligand. We found good agreement between model predictions and experimental 
data, both of which suggested that IGF-I triggered activities of Akt and ERK are both strongly 
upregulated in the LOI vs. WT cells (Fig. 4.1B). Therefore, this ligand, unlike IGF-2, does not 
trigger re-balancing of the network activity. This differential effect of IGF-1 vs. IGF-2 in LOI cells, 
was not due to its inability to upregulate IGF1R in these cells (Fig. 4.1C). This upregulation was 
expected based on enhancement of Erk signaling, and it indeed occurred. Rather, the model 
strongly suggested that the differential affinity of IGF-1 to the receptor complexes can result and 
into less pronounced internalization of activated receptors thus permitting enhancement of Akt 
activity in LOI cells. his result suggests thatTherefore network rebalancing can occur due to 
enhanced expression of a growth factor ligand, but this effect is not universal and depends on 





Figure 4.1 : LOI and WT response to IGF-1  
A) LOI and WT cells were immunoprecipitated with IGF-1R abs and probed with IGF-1R and IR. B)LOI and WT cells 
were stimulated with IGF-1 for the indicated time points and analysed by Western blotting. The fold increase in pAkt 
and pErk over control (t=0) are plotted as a function of time (error bars). The IGF-2 signaling model was trained on 
pAkt and pErk response to IGF-1 stimulation. The model parameters were re-estimated to fit the average pAkt and 
pErk profiles as explained in the text.  The model prediction for WT responses was obtained and plotted (blue solid 
lines) and compared with experimentally observed values (blue error bars). C)LOI and WT cells were stimulated with 




Chapter 5 : Stochastic model for the stem cell compartment 
 
The model follows the stem-transit amplifying-terminally differentiated program of the crypt as 
shown in Fig 1. The stem cell pool has no input and is self-contained. Stem cells can divide into 
two daughter cells and hence generate an event, the dividing cells can either remain as stem 
cells or differentiate and become transit amplifying cells. The transit amplifying cells proliferate 
rapidly and stay as transit amplifying cells for integral number of cell cycles and then 






Figure 5.1 :  Model description of the Stem-Transit amplifying-Terminally differentiated cells  renewal program of the 
colonic crypt homeostasis. 
Stem Cell Compartment:  The stem cell pool is composed of cells that proliferate slowly, renew 
indefinitely and are responsible for the maintenance of the crypt. The stem cells reside at the 
bottom of the crypt and are relatively few in number.  Owing to the inherent stochasticity and 
the probabilistic nature of cell division and differentiation, the number of stem cells in a crypt at 
any given time instant of is a random variable with a mean value and variance. Consequently, as 
a function of time the number of stem cells in a crypt can be described as a random process.  Let 
NS(t) be that random process. Events in this compartment are generated when a stem cell 
undergoes mitosis, say at  𝑡 = 𝑡𝑎 , and at each cell division one of 3 things can happen, 
a) NS(𝑡𝑎)  decreases by 1 to NS(𝑡𝑎) = NS(t) - 1, where 𝑡 < 𝑡𝑎,  a case of symmetric division and 
when both the daughter cells differentiate and leave the compartment,  
b) NS(𝑡𝑎) remains the same, NS(𝑡𝑎) = NS(t), where 𝑡 < 𝑡𝑎,  a case of asymmetric division and 
when one of the daughter cell stays in the compartment while the other daughter cell 
differentiates and leaves the compartment and , 
c) NS(𝑡𝑎)  increases by 1 to NS(𝑡𝑎) = NS(t) + 1, where 𝑡 < 𝑡𝑎, a case of symmetric division where 
both the daughter cells remain as stem cells and stay in the compartment. 
If the time sampling is sufficiently fine, we can avoid the situation of two cells dividing at the 
same time and thus simplify the system specification.  
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Figure 5.2 : The three forms of cell division in the stem cell pool  
 
Let { 𝑡0, 𝑡1, 𝑡2, … . . 𝑡𝑛, 𝑡𝑛+1, … .. } be the time instants at which events occur in the stem cell 
compartment and let { S1, S2, S3 …, Sn, Sn+1, …  } be the corresponding time intervals between 
successive cell divisions such that 𝑆1 = 𝑡1 − 𝑡0 is the time to the first division and S2 is the time 
interval between the second and the first cell division and so on. We can safely assume that S1, 
S2,.. etc are a sequence of independent, identically distributed random variables such that 
0 < 𝐸[𝑆𝑖] < ∞ be true ∀ 𝑖, where 𝐸[. ] is the expectation operator.   
Let 𝐼(𝑡) be the indicator function that gives the jump in 𝑁𝑆(𝑡) at each time instant, such 
that 𝑁𝑆 (𝑡𝑖 + ∆) −𝑁𝑆(𝑡𝑖 − ∆) =  𝐼 (𝑡𝑖) be the height of the jump at 𝑡 = 𝑡𝑖 for any arbitrarily 
small ∆.  𝐼(𝑡) is the amount by which 𝑁𝑆 changes i.e. by 0, +1 or -1 corresponding to the 3 
outcomes of cell division. Also, let  𝐽𝐼 be such that 𝐽𝐼 = ∑ 𝑆𝑛𝐼𝑛=0  , the sum of all time intervals 
between cell divisions (also called the holding times in random processes parlance). 
𝑁𝑆 (𝑡) defined as 𝑁𝑆 (𝑡) =  ∑ 𝐼 (𝐽𝑛 ≤ 𝑡 )∞𝑛=1  is a renewal process. Assuming wide-sense 
stationarity / time invariance 𝑁�𝑆 (𝑡) = 𝐸[𝑁𝑆(𝑡)] = 𝑁�𝑆 is the average number of stem cells 
expected to be found in a crypt.  
Let us define {𝑊1,𝑊2,𝑊3, … . .𝑊𝑛,𝑊𝑛+1, … } as the events that lead to stem cells 
differentiating and leaving the compartment. This happens when i) when both the daughter 









1. Symmetric division 
with both daughter 
cells differentiating. 
2. Asymmetric division 
and differentiation 
3. Symmetric division 
with two daughter 




in 𝑁𝑆 (𝑡) and ii) when one daughter stem cell differentiates and leaves the compartment 
corresponding to a jump of 0 in 𝑁𝑆 (𝑡).  Since its reasonable to assume that the probabilities of 
symmetric and asymmetric differentiation in crypt stem cells don’t change with time, 
{𝑊1,𝑊2,𝑊3, … . .𝑊𝑛,𝑊𝑛+1, … } is a set of independent and identically distributed random 
variables. So 𝑊1 and its sample space can defined as 
𝑊1 = �
+2             𝑏𝑜𝑡ℎ 𝑑𝑎𝑢𝑔ℎ𝑡𝑒𝑟 𝑠𝑡𝑒𝑚 𝑐𝑒𝑙𝑙𝑠 𝑙𝑒𝑎𝑣𝑒 𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡
+1        𝑜𝑛𝑒 𝑑𝑎𝑢𝑔ℎ𝑡𝑒𝑟 𝑠𝑡𝑒𝑚 𝑐𝑒𝑙𝑙 𝑙𝑒𝑎𝑣𝑒𝑠 𝑡ℎ𝑒 𝑐𝑜𝑚𝑝𝑎𝑟𝑚𝑒𝑛𝑡
   0       𝑛𝑜𝑛𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑎𝑢𝑔𝑡𝑒𝑟 𝑐𝑒𝑙𝑙𝑠 𝑙𝑒𝑎𝑣𝑒 𝑡ℎ𝑒 𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡 
� 
And the associated probabilities can be written as, 
𝑝𝑊1 = �
𝑝  𝑓𝑜𝑟 𝑊1 =  +2
𝑞  𝑓𝑜𝑟 𝑊1 =  +1
𝑟  𝑓𝑜𝑟 𝑊1 =     0
� ;   𝑤ℎ𝑒𝑟𝑒 𝑝 + 𝑞 + 𝑟 = 1 
Also let 𝐸[𝑊1] =  ∑  𝑊1 𝑊 𝑝𝑊1 be such that 0 < 𝐸[𝑊1] < ∞, then the random variable 
𝑌𝑡 = ∑ 𝑊𝑖𝑡𝑖=1  defined over  {𝑊1,𝑊2,𝑊3, … . .𝑊𝑛,𝑊𝑛+1, … } and {𝑆1,𝑆2,𝑆3, … . . 𝑆𝑛,𝑆𝑛+1, … } is a 
renewal reward process. The convenience of formulating the cells differentiating and exiting 
the stem cells compartment as a renewal reward process is in being able to relate fundamental 
biological quantities of the crypt dynamics using fundamental renewal reward theorems.  
 The important parameters that define the stem cell compartment are the number of 
stem cells at any point in time, the average cycling time of stem cells and the probabilities of 
symmetric and symmetric division. Directly from the model definition the number of stem cells 
in the compartment is given directly by 𝑁𝑆𝐶(𝑡), the probabilities of division are given by p, q and 
r and as shown below the average cycling time can be expressed in terms of these parameters. 









The equation basically relates the time average or rate of exit of stem cells (the left hand side) 
from the stem cell compartment to the probabilities of the various mitosis outcomes and the 
average cell cycle time (right hand side of the equation) in the stem cell compartment. 𝐸[𝑊1]  
can be enumerated as, 






Figure 5.3 : The renewal process and renewal reward process : 
Every time a stem cell divides, based on either of the 3 cell division outcomes highlighted in the text 𝑵𝑺(𝒕) changes by 
the corresponding 𝑰(𝒕) which then forms the basis of the renewal reward process.  
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 𝑤ℎ𝑒𝑟𝑒 𝐶 𝑖𝑠 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙 𝑐𝑦𝑐𝑙𝑒 𝑡𝑖𝑚𝑒 𝑎𝑛𝑑 𝑁�𝑆𝐶  𝑖𝑠 𝑡ℎ𝑒 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑒𝑚 𝑐𝑒𝑙𝑙𝑠. 
Use if the above equation makes intuitive sense because if there were N stem cells with a cell 
cycle time of C hours, we would expect a cell to divide every C / N hours on an average. Thus, we 
have 
𝑅𝑆𝐶𝑜𝑢𝑡 =  
𝑁�𝑆𝐶 × (2𝑝 + 𝑞)
𝐶
 
as the equation for the rate of exit of stem cells from the compartment. 
The Transit Amplifying Compartment : The cells that comprise the transit amplifying 
compartment proliferate prodigiously to make up for the high rate of loss of cells from the 
terminally differentiated compartment and the very low proliferation rate of the cells in the 
NS(t) 


















stem cells compartment. The stem cells exiting from the stem cell compartment enter the 
transit amplifying compartment, go through cycles of mitosis and then leave the compartment.  
Given the enter, proliferate and exit nature of this compartment, it can be analyzed purely as a 
rate amplifier. Assume an epoch of time 𝐶𝑇𝐴 equal to the average cell cycle time of the transit 
amplifying cells. The number of cells that enter during 𝐶𝑇𝐴 is determined by the rate of exit of 
stem cells 𝑅𝑆𝐶𝑜𝑢𝑡 such that 𝐾 = 𝑅𝑆𝐶𝑜𝑢𝑡  × 𝐶𝑇𝐴 is the number of cells that enter the transit 
amplifying compartment during a time 𝐶𝑇𝐴. Every 𝐶𝑇𝐴 that elapses the 𝐾 cells double and 
another 𝐾 cells enter the compartment. If the first set of 𝐾 cells that enter stay for 𝐿 = 𝑙 ×  𝐶𝑇𝐴 
hours where 𝑙 is any integer, then rate of exit of cells from the compartment can be easily given 
as  
𝑅𝑇𝐴𝑜𝑢𝑡 =  2𝑙 × 𝑅𝑆𝐶𝑜𝑢𝑡 
The number of cells found in the TA compartment can also be easily expressed as, 
𝑁𝑇𝐴 =  𝐾 × � 20 + 21 + 22 +  … . . +2𝑙 � =  𝐾 × �2𝑙+1 −  1� 𝑐𝑒𝑙𝑙𝑠 
Prediction of stem cell division time in homeostasis: 
A typical human colonic crypt contains on an average about 82 levels of cells from the bottom to 
the top of the crypt. The bottom most level contains 1 cell and levels 2 to 7 contain 6, 12, 18, 24, 
30 and 36 cells respectively. The straight portion of the crypt from levels 8 to 82 contain 42 cells 
per each level adding to about 3193 cells per crypt (Boman et al., 2008). From stem cell markers 
staining data, Musashi-1 and Lgr5, it is evident that the stem cells predominantly populate the 
bottom 3 to 4 levels of the crypt. There are about 19 cells in the bottom 3 levels while there are 
37 cells in the bottom 4 levels. For the purposes of an illustrative example we can take the 
average of these two numbers, 30 as the number of stem cells in a crypt.  Data from S-phase 
labeling and Ki-56 labeling indicate that levels 4 to 45 which have more than or about the 
average level of S-phase staining can be considered to be the transit amplifying compartment 
comprising of rapidly proliferating cells. From the distribution of the number of cells / level,  
levels 4 to 45 contain 1686 cells. The remainder 3193 – (1686+30) =  1477 is the number of cells 
in the terminally differentiated compartment / crypt. 𝑁𝑆𝐶 = 30,𝑁𝑇𝐴 = 1686 𝑎𝑛𝑑 𝑁𝑇𝐷 = 1477  
respectively.  
 The crypt turnover rate is about 5 days and it’s expected that 95% of the cells in a crypt 
are turned over in a 5 day period, thus the rate of loss of cells from the crypt or the terminally 
differentiated compartment is 𝑅𝑂𝑢𝑡 =
0.95 ×3193
120
= 25.27 cells / hour. Since there is almost no 
proliferation in the terminally differentiated compartment, the average rate of cells exiting out 
of the Transit Amplifying compartment is the same,  𝑅𝑇𝐴𝑜𝑢𝑡 = 𝑅𝑂𝑢𝑡 . From the previous section 
we have,  
𝑅𝑇𝐴𝑜𝑢𝑡 =  2𝑙 × 𝑅𝑆𝐶𝑜𝑢𝑡 




Previous work in estimating critical parameters of the crypt dynamics have resulted in 
many estimates of parameters. Here we use some of the parameters available in literature and 
test the predictions of the model and hence its validity. The number of stem cells in a crypt is 
put at about 30 / crypt, so 𝑁�𝑆𝐶 = 30 cells / crypt. Given the very unlikely chance of symmetric 
division and the more common occurrence of an asymmetric division with the stem cells, we can 
use 𝑝 = 0.05,𝑞 = 0.9 and 𝑟 = 0.05. Since the stem cells proliferate a lot slower than the cells of 
the transit amplifying compartment, we test a prediction for the stem cell cycling time 
𝐶 = 90 ℎ𝑜𝑢𝑟𝑠. With these values  
 





 = 0.333 cells / hour 
𝑅𝑇𝐴𝑜𝑢𝑡 =  2𝑙 × 𝑅𝑆𝐶𝑜𝑢𝑡 
𝑙 = log2 �
25.27
0.33
� = 6.26 
Thus a value of 𝑙 = 6.26 indicates that cells in the transit amplifying compartment cycle about 
6.26 times or undergo about 6.26 successive divisions before they become terminally 
differentiated. Also from literature we have the cell cycle times in the transit amplifying 
compartment as 𝐶𝑇𝐴 = 29.9 𝑡𝑜 39.9 ℎ𝑜𝑢𝑟𝑠.  Thus 𝑁𝑇𝐴 is bound by,  
𝑁𝑇𝐴 =  
𝐾 ×  �1 − 2𝑙+1�
(1 − 2)
=  
(35 ± 4.9) × 0.33 × (1 − 27.29)
−1
= 1800 ± 266 𝑐𝑒𝑙𝑙𝑠 
Where 𝐶𝑇𝐴 = 35 ℎ𝑜𝑢𝑟𝑠 is the mean value. This average value of 𝑁𝑇𝐴 = 1800 cells 
approximately matches 1686, the of number of cells in the transit amplifying compartment 










Network Re-balance – IGF-2 LOI signaling network is an example of a re-balanced 
network. Re-balancing refers to the altering in the signal strength of one downstream pathway 
at the expense of the other parallel pathway. Although Akt and Erk are activated beginning at 
the IGF-1R, their relative strengths can be varied by affecting any of the receptor trafficking 
processes or the adapter molecules that connect to Akt and Erk signaling. In the IGF-2 LOI cells 
Akt signaling is attenuated while Erk signaling is concomitantly enhanced. This re-balancing in 
signaling strengths can consequently affect in proportional ways the downstream targets and 
processes mediated by both Akt and Erk. Since Erk mediates amongst other things the growth 
and proliferation of cells, network re-balance puts the cells in the “fast-lane” as a rapidly 
proliferating group of cells. 
Growth factors and growth factor receptor signaling can have significant consequences in the 
face of network re-balancing as Akt and Erk activation are a common theme amongst all growth 
factor signaling systems (Oda et al., 2005). A flavor for the effect of re-balancing can be obtained 
by looking at the effect of different growth factors on cells that express receptors for them. By 
virtue of their differential coupling to the mechanisms that regulate and activate Akt and Erk 
different growth factor receptors can activate Akt and Erk to different degrees (Haugh and 
Meyer, 2002) (Park et al., 2003). This activation of Akt and Erk to different degrees can also 
determine opposing cell fates in systems where Akt and Erk signaling strengths determine cell 
fates. EGF (Epidermal growth factor) and PDGF (Platelet derived growth factor) are two growth 
factors that can elicit different Akt and Erk signaling signatures in cells. While EGF is known to 
produce strong Erk signaling, PDGF signals more via the PI3K pathway to preferentially activate 
Akt (Normanno et al., 2006) (Tallquist and Kazlauskas, 2004). In human Mesenchymal stem cells 
it was shown that EGF signaling caused the cells to differentiate and form bone-forming cells 
while PDGF did not induce the differentiation although the two growth factors appeared to 
recruit 90% of similar phospho-tryosine proteins (Kratchmarova et al., 2005). PI3K was shown to 
be the control point as PDGF strongly activated Akt signaling and inhibition of Akt signaling 
induced differentiation of cells (Kratchmarova et al., 2005). 
In PC-12 cells, which are a neural progenitor cell line that differentiates into neurons when 
treated with NGF (Neural growth factor), it was shown that there existed a two-dimensional 
phospho-Akt and phospho-Erk landscape that determined differentiation versus proliferation in 
cells treated with NGF (Chen et al., 2012). This boundary was shown to be a curved surface and 
invariant in position to various perturbations of upstream elements of the Akt and Erk pathway 
(Chen et al., 2012). Network re-balancing thus is a methodology whereby cells can alter their 
downstream Akt and Erk signaling strengths and potentially alter proliferation, growth rates, 





Erk signaling determines and sustains the IGF-2 LOI phenotype – 
Erk signaling solely mediates and sustains the IGF-2 LOI phenotype. Erk is shown to mediate the 
long-term transcriptional increase in IGF-1R and also mediate the ubiquitin driven degradation 
of IGF-1R.  As far as we know, there hasn’t been any evidence so far in the literature about Erk 
mediated positive transcriptional regulation of IGF-1R although a few pieces of connecting 
evidence can be suggested. The IGF-1R regulatory region, surprisingly, lacks the canonical TATA 
box or the CAAT motifs that are used in eukaryotes as transcription start sites and instead is 
highly GC rich. The transcription is initiated from a special initiator motif that is adjacent to 
upstream Sp1 sites. Sp1 is a ubiquitous zinc-finger based nuclear transcription factor that 
stimulates transcription from RNA-pol II based promoters (Werner, 2012).  
Amongst the many known factors that bind to IGF-1R, p53 in its wild-type state is a tumor 
suppressor gene product that stops progression through the cell cycle stages when in its 
phosphorylated state. p53 in its nuclear localized state binds to specific sequences in the 
promoter of many genes thereby regulating it. p53 binds to the IGF-1R promoter region thereby 
suppressing its expression while mutations in p53 that occur in the central DNA binding region 
of the protein relieve the suppression and increase IGF-1R expression (Werner et al., 1996). 
Another protein that closely associates with the status of p53 in the cells is the nuclear 
transcription factor Wilms tumor suppressor gene product (WT1) which structural studies have 
shown to possess multiple binding sites upstream and downstream of the transcription initiation 
site of the IGF-1R promoter. It has been shown that depending on the mutant status of the p53 
protein in the cell, WT1 exerts its suppressive or oncogenic properties on IGF-1R transcription 
i.e. in a p53 mutant system WT1 cannot suppress the increased expression of IGF-1R. Mutations 
in WT1 are implicated in Wilms tumor which is a pediatric form of renal malignancy. BRCA1 is a 
tumor suppresser which functions as a regulator in cell-cycle progression, DNA damage, repair 
and maintaining genomic integrity. Mutations in BRCA1 drastically enhance the risk of breast 
cancer and ovarian cancer. Although BRCA1 hasn’t been shown to bind to the IGF-1R promoter 
region directly, it can interact and modulate the activity of other proteins that bind. In prostate 
cancer, it has been shown that BRCA1 interacts with Androgen Receptor (AR) and exerts a 
repressive effect on IGF1R (Schayek et al., 2009)  
Evidence for pCREB regulation of IGF-1R comes from prostate cancer where the cancer is usually 
androgen responsive in the beginning and then progresses to an androgen independent, 
aggressive and resistant to therapies state. It has been shown that sex hormones binding to 
both AR and ER markedly upregulate IGF-1R in prostate cancer cells. This upregulation does not 
involve the binding of the receptors to the DNA responsive elements instead it has been shown 
that it involves the c-Src / Extracellular signal regulated kinase (Erk1/2) and the PI3k pathways 
(Genua et al., 2009). CREB (cAmp response element binding protein) is a cellular transcription 
factor that binds to regions called the cAmp response elements in the regulatory regions of 
many target genes and increase their transcription. ER and AR both cause phosphorylation of 
CREB at Ser133 enabling the binding of CREB to CBP/P300 (CREB binding protein) and causing 




promoter contains 3 CREB sites in the 5’ UTR region. It was also shown that phospho-CREB 
binding to IGF1R promoter in response to sex steroids was necessary for IGF-1R transcriptional 
increase (Genua et al., 2009) Given the ubiquitous nature of Erk signaling, activation of Erk 
signaling also causes a Calcium flux, a cAmp response and hence phosphorylation of CREB and 
the activation of downstream targets(Wu et al., 2001). Similarly the PI3k/Akt pathway is also 
known to phosphorylate CREB at Ser133 and activate downstream target genes (Du and 
Montminy, 1998). Thus both Erk1/2 and the PI3k/Akt pathways can activate CREB and induce 
the recruitment of CBP to CREB 
Ubiquitination is a post-translational modification, which apart from marking a protein for 
degradation via the proteasomal machinery, is been known to play an increasingly important 
role in receptor mediated endocytosis and Erk regulation (Acconcia et al., 2009; Nguyen et al., 
2013). Ubiquitination of the receptor (EGFR, IGF-1R) and associated adaptor proteins has been 
found to be a critical step in receptor mediated endocytosis and Erk activation (Nguyen et al., 
2013). Many E3 ligases are known to be associated with growth factor receptor signaling and 
internalization. c-Cbl, Nedd4 and Mdm2 are 3 known E3 ligases that have been associated with 
ubiquitination of receptors (Nguyen et al., 2013) . Although there is considerable evidence of a 
number of players in the MAPK pathway doubling up as ubiquitin agents, a role for Erk in 
mediating receptor ubiquitination has so far not been reported in our understanding. 
Propagation of network re-balance and apoptotic susceptibility - Given 
that Akt mediates a strong pro-survival signal via inhibition of Caspase-9, phosphorylation of Bad 
and Bcl-2, it was expected that Akt signaling changes be reflected in the balance of anti-
apoptotic proteins. Erk signaling on the other hand, as far as we know, has not been connected 
to pro-apoptotic signaling although there is evidence for anti-apoptotic phosphorylation of Bad 
(Jin et al., 2002). The suggestion that Erk signaling can increase pro-apoptotic Bax implies a 
penalty for fast cycling cells in terms of the loss of the stoichiometric excess of anti-apoptotic 
Bcl-2 over pro-apoptotic Bax in IGF-2 LOI cells. This mechanism of Bax regulation by Erk signaling 
is unknown and might involve other players like cMyc. cMyc which is a central regulator in many 
homeostatic processes has been shown to influence Bax levels (Juin et al., 2002) and is 
dependent on both Akt and Erk signaling for its accumulation and stabilization (Sears et al., 
2000). Thus by virtue of the propagation downstream of the re-balance in Erk – Akt signaling, 
LOI cells re-balance their pro and anti- apoptosis signaling by decreasing Bcl-2 levels and 
increasing Bax levels.   
 
“Oncogene addiction” – It is a known fact that cancers of all forms, malignancies and 
tissue types are borne out as a result of the accumulation of multiple genetic abnormalities and 
epigenetic changes harbored over long periods of time (Greenman et al., 2007). Although the 
genetic aberrations and epigenetic changes can be found in a wide variety of regulators from 
growth factors, tumor suppressors to phosphatases, some cancers are reliant exclusively on a 




Thompson, 2009). Such cancers stop growing and in some cases restore normal health in 
patients when the single driver mutation is reversed or inhibited thus exhibiting “oncogene 
addiction” or the possession of an “Achilles’ heel” in the mutation (Weinstein, 2002; Weinstein 
and Joe, 2008). A few mechanisms have been proposed in literature to explain this dependence, 
since cancer cells are known to have dysregulated many genes and their regulators, the 
signaling network is expected to be quite different from normal wild-type cells. These altered 
signaling networks might be rewired to the extent that different genes might end up performing 
different cellular roles to different extents as compared to WT cells and thus interruption of a 
key driver in these networks might adversely affect the cellular outcomes as opposed to Wild-
type normal cells (Weinstein and Joe, 2008). Other studies have proposed a mechanism called 
“Oncogene Shock” where activation of critical oncogenes can attenuate the rates of pro-survival 
and pro-apoptotic signals (Sharma et al., 2006). In this situation, because of the greater 
decrease in the rates of pro-survival signals as compared to pro-apoptotic signals, in the face of 
inhibition of the oncogene there is greater cell death and decreased growth.  
IGF-2 LOI cells both in-vivo and in in-vitro culture show an addiction to IGF-2 although these cells 
are not cancerous in nature. An increase in IGF-1R expression, coupled with an increased 
internalization rate drives an increased Erk signaling which sustains the increased IGF-1R 
expression and the LOI phenotype. The re-balance in Erk and Akt signaling is shown to alter the 
anti and pro- apoptotic balance by altering the levels of Bcl-2 and Bax. Thus the LOI cells by 
virtue of their increased Bax and decreased Bcl-2 are more susceptible to loss of IGF-2 signaling 
via the inhibition of the IGF-1R kinase. Although the re-balance of Bax and Bcl-2 levels as shown 
here is conceptually similar to the “Oncogene Shock” mechanism described above, important 
differences remain – The re-balance is not directly due to an oncogene as it is in the former 
case, the IGF-2 LOI cells have a plausible mechanism for generating the re-balance and the IGF-2 
LOI system’s addiction is due to change in the levels of pro and anti-apoptotic proteins and not 
by the change in their rates of attenuation.   
Although a mechanism for IGF-2 addiction has been proposed here this is by no means a general 
solution for a mechanistic understanding of oncogene addiction. It could very well be that the 
oncogene that drives the addiction along with the other genetic and epigenetic changes could 
have re-wired the underlying signaling network or it could be a combination of driver mutation 
induced change in the network coupled with re-balancing of pro- and anti– apoptotic factors. 
More so, since not all cancers show the addiction to an oncogene this could very well be limited 
to a particular form and have different mechanistic underpinnings in different cancers. More 
research would be needed to identify differences and similarities. 
Therapeutic Window – One of the requirements of effective treatment of a drug is an 
existence of a “therapeutic window” wherein the dosage of the drug is deemed to be effective 
without necessarily causing a system wide reaction or adverse side-effect. In terms of cancer 
treatment it can be seen as the ability to exclusive target and eliminate cancer cells while not 
much affecting normal cells and homeostasis. As seen here, the Bax/Bcl-2 re-balancing and the 




IGF-2 addiction. A dose of IGF-1R kinase inhibitor in this window has twice the effect on LOI cells 
as it has on WT cells. Although LOI of IGF-2 is not a cancer or a tumor, the in-vitro survival curves 
indicate that, the cells can be safely targeted by taking advantage of the therapeutic window 
thus diminishing the chance of the development of LOI of IGF-2 into colorectal cancer.  
IGF-2 vs IGF-1 -  Although IGF-2 and IGF-1 are a part of the Insulin signaling superfamily, 
signaling through the same set of receptors and receptor complexes albeit with different 
affinities, only IGF-2 is imprinted evolutionarily and not IGF-1. More evidence and proof for the 
selective silencing / imprinting of IGF-2 comes from the signaling responses of IGF-1. Although 
IGF-1 triggers an increased expression of IGF-1R via an increased Erk signaling it doesn’t create 
the re-balance in Akt and Erk signaling as seen in LOI cells when stimulated with IGF-2. 
Presumably, this lack of re-balance in Akt and Erk could preserve the balance of the pro- and 
anti- apoptotic proteins Bax and Bcl-2 as seen in WT cells. This further illustrates the special 
nature of IGF-2 signaling because any transient increase in IGF-2 levels (similar to a temporary 
loss of imprinting scenario) which can cause increased growth and size can be quickly 
ameliorated when the IGF-2 increase disappears because the IGF-2 addiction mechanism and 
the therapeutic window ensures that loss of IGF-2 results in cell death, reduction in growth and 
a return to normal homeostasis. Such a mechanism would be exclusive to IGF-2 and not IGF-1 
and underscores the importance of IGF-2 as an imprinted gene. 
Development of colonic crypts - Intestinal and colonic crypts develop from the 
embryonic primitive gut post birth by invagination of the epithelium into the mesenchyme. A 
recent theory that was proposed to explain the attainment of the final steady state crypt length 
in terms the optimal control theory and time to full length crypt called the “bang-bang” theory 
proposed a two-step strategy of an initial pool of stem cells that expand to the required final 
number of stem cells followed by a second step of asymmetric division of stem cells into 
differentiated cells to produce the requisite number of differentiated cells (Itzkovitz et al., 
2012). Since growth factor signaling is required to switch from an all stem cell population to a 
mixed population, IGF-2 LOI should result in maybe a greater set/pool of stem cells followed by 
a greater number of differentiated cells. More light could be shed on the development scheme 
of crypts in the intestine and colon by studying the development of intestinal tissue of the IGF-2 
LOI system.  
Stochastic Model - We have presented here a stochastic random process based model for 
the homeostasis and organization of the colonic crypt.  The pool of stem cells is modeled as a 
renewal process with every cell division creating the event and the subsequent decision to 
either remain a stem cell or differentiate creating the counting process. The differentiation and 
exit of cells from the stem cell pool is modeled as a renewal reward process and by using the 
fundamental theorem of the reward process we have been able to quantify the rate of exit of 
cells from the stem cell pool.  
The stem cells have been the most elusive and secretive of all the cells in the colonic epithelium 




mark the stem cell pool. Much less is known either about the nature of the symmetric or 
asymmetric division in the stem cell pool and the probabilities with which they occur. The very 
infrequent if not dormant cell cycling times of the stem cells have also been a question that 
hasn’t been resolved adequately due to the extreme difficulty in marking these cells for 
proliferation markers. Using the equation for the rate of differentiation of the stem cells and 
numbers obtained from the general knowledge of the crypt dynamics we tested a value for the 
cell cycling time of the stem cells. Using this value we were able to verify, within bounds, the 
approximate number of cells expected to be found in the transit amplifying compartment and 
thus validating the value for the stem cells cycling time. 
The advantage of using the renewal and the renewal reward process is that some of the simple 
yet powerful theorems and results derived for these stochastic processes can be used to 
describe the processes and dynamics of the crypt evolution and organization. The stem cell pool 
and the rate of differentiation of the stem cells determine the existence of the crypt and its size 
respectively.  Apart from the mean rate, the variance of the rate of differentiation of stem cells, 
which can also be analytically expressed, gives a wealth of information regarding the 
stochasticity in crypt length and numbers observed. Renewal reward theory enables us to 
analytically express the variance as well and this in turn can lead to the development of other 
aspects of crypt dynamics, namely feedback regulation, that is not explicitly discussed here.  
It can also be easily seen that this model can, in principle, be used to analyze the effects of 
mutations in the stem cell compartment that can lead to colon associated cancers. For example 
the APC mutation leads to an increase in the probability of symmetric cell division where both 
the daughter cells remain stem cells thereby increasing the number of stem cells. This can then 
easily lead to a decrease in the differentiation rate and thus to a reduced pool of transit 
amplifying cells. Thus the corresponding  stochastic models not only enable a more faithful 
representation of the inherent randomness in crypt biology but allows derivation of expected or 
average results that are observed in experiments and provide a handle to discuss dynamical 






Materials and Methods 
 
Materials : Anti - pAkt, pErk1/2, IGF1R, IR, Ubiquitin, pMek1/2, cMyc, Bax, Caspase-9, Caspase-3 
antibodies, LY294002, U0126 were purchased from Cell Signaling Technology, MA. Anti α-
tubulin mouse antibody was from Sigma-Aldrich.  Anti Bcl-2, Bak-1, Bcl-Xl were from SantaCruz 
Biotechnologies, CA. Goat Anti-mouse, anti-rabbit, Alexafluor 480,594,633 conjugated 
secondary antibodies, CellMask deep-red whole cell stain, Hoechst, FM143-fx dye, Streptavidin 
conjugated and Protein A/G dynabeads, iBlot dry blotting apparatus  were from Invitrogen 
technologies, CA. Alamar blue was from AbD Serotech, CO. MDC, Monensin Sodium, MG-132, 
Okadoic Acid were purchased from EMD Millipore, USA. 
Western Blotting : Cells were grown to 95% confluency, serum starved overnight, treated to 
experimental conditions and harvested in denaturing SDS based lysis buffers, suspended in 4x 
loading buffer and heated to 95 degC for 5 minutes and stored for archival at -20degC. Lysates 
(about 20µg) are reduced with DTT and subjected to gel-electrophoresis in precast Bis-Tris gels 
under reduced conditions and transferred to 0.2µ Nitrocellulose membrane in a dry-transfer 
iBlot apparatus. Membranes were blocked with 5%BSA in PBS and then incubated with the 
relevant primary antibody followed by the secondary with 5 to 6 washes in washing buffer in 
between. The membranes were developed using PicoWest chemiluminescence substrate and 
imaged using BioRad imaging station. The images of the blots were then quantified using the gel 
band intensity analysis macro in ImageJ. 
Immunofluorescence : Cells were seeded on 35 mm Mattek dishes and allowed to attach for 10 
to 12 hours. Cells were then serum starved overnight in DMEM media with 0%FBS and 
stimulated with IGF-2 of indicated concentration for the indicated period of time. The cells are 
then washed in ice-cold PBS and fixed in 4% Fomaldehyde. The cells are then permeabilized with 
0.1% TritonX-100 in PBS and then blocked with 10% goat serum for 1 hour. The cells are 
incubated with primary antibody at the specified concentration in blocking buffer and incubated 
overnight at 4degC. After washing thoroughly the cells are incubated with the appropriate 
secondary antibody, Hoechst dye and CellMask Deep Red at the specified concentrations for 1hr 
at room temperature. The cells are then washed thoroughly in PBS and imaged on a Zeiss 
AxioObserver Z1 inverted microscope with DAPI, GFP/FITC, Cy3/Rhodamine and Cy5 excitation 
and emission filter sets. The fluorescence signal from the target protein is quantified using 
custom Matlab code based on the Watershed algorithm. Using the Hoechst stain for the nucleus 
and the CellMask stain for the cytoplasm, the cell boundary is marked and the fluorescence 
signal quantified as mean signal / cell. 
Cell survival assay : Cells were seeded at a density of 2000 cells/well in a dark walled, 
transparent bottom 96 well assay plate overnight and then serum starved for 24 hours followed 
by 24 hours of NVPAEW541 treatment. 10% Alamar blue was added to each well and 
fluorescence measured at 590nm in a plate reader. No drug control was used to express the 




Annexin V : Cells were grown to 95% confluency, serum starved overnight, treated with NVP 
drug, trypsinized to make single cell suspension, washed in wash buffer and incubated with 
AnnexinV:PE as indicated by the BD protocol. The cells were also counterstained with 7-AAD to 
exclude dead cells. The cells were analyzed by flow cytometry, gated and plotted with AnnexinV 
against sidescatter. 
Cell surface biotinylation and receptor internalization rate : Cells are grown in flasks to 95% 
confluency and serum starved overnight. Cells are washed in ice-cold PBS and incubated with 
Supho-NHS-SS-Biotin to label all cell surface receptors. The cells are washed and stimulated with 
IGF-2 at 37degC to aid internalization of the receptors. After stimulation the remaining biotin on 
the receptors on the surface are cleaved with glutathione reducing agent and the cells are lysed 
in IP buffer. The lysate is then incubated with streptavidin coated dynabeads to pull down biotin 
labeled receptors and analyzed by Western blotting. The blots are then probed with Anti-IGF1R 
antibodies to quantify internalized IGF1R. 
Internalization rate with FM143FX : Cells were seeded on Mattek dishes and left overnight for 
attachment. They were then serum starved overnight and incubated with 100uM FM143FX dye 
for 15 minutes at 4degC for the dye to stain the cell surface. The dye is then removed, cells 
washed to remove excess of the dye and the DMEM medium (without phenol red) replaced 
back. The cells were incubated with IGF-2 at 37degC for various times. After the set time points 
the cells were washed, fixed and imaged for the internalized dye. Cells were also counterstained 
with Hoechst 33342 and HCS CellMaskTM  Deep Red (Life Technologies, CA) to stain the nucleus 
and the cytoplasm. The internalized dye was then quantified by using the nuclear and 
cytoplasmic stain as a mask to delineate the cell using custom Matlab code based on the 
Watershed algorithm. 
qRT-PCR assays : Cells were grown to confluence and collected as pellets in RNAprotect cell 
reagent (Qiagen, CA). According to instructions of the RNEasy kit (Qiagen, CA) total RNA was 
extracted from the cells. The RNA was then converted to cDNA according to the instructions of 
the QuantiTec Rev. Transcription kit (Qiagen,CA). Using custom Taqman assays 
(AppliedBiosystems, CA)  for the various gene targets, the cDNA was added to the Taqman 
probes in triplicates in a pcr mix in 384 well plates. Using multiple dyes for the gene of interest 
and β-actin in the same well, the fold expression of the gene of interest normalized to β-actin is 






Computational model of IGF-2 signaling 
 
IGF-2 binds cell surface receptors (IGF1R and IGF1R:Insulin Receptor (IR) heterotetramers) and 
autophosphorylates them on their cytoplasmic tails (R.2 and R.5 below). The phosphorylated 
receptors are aggregated into clathrin coated pits and internalized into vesicles (R.6). The 
plasma membrane localized receptors activate Akt (through the PI3K pathway) (R.9). The 
internalized receptors in the vesicles activate Erk (R.10) through a sequence of adaptors and 
signaling cascades. A fraction of the internalized receptors are degraded via proteasomal and 
lysosomal pathways (R.7) and another fraction is recycled back to the surface of the cell (R.3). 
We have shown that activated Erk can negatively regulate IGF1R by ubiquitylating cell surface 
IGF1R (R.4) while it can positively regulate IGF1R by its increased transcription over 24hours 
(R.12). Phosphorylated Akt is acted upon by the phosphatase PP2A to return Akt to its de-
phosphorylated state (R.8) while Erk is known to exert a negative feedback onto itself and 
causes the return in its phosphorylated state to baseline (R.11). While the net concentrations of 
all protein species (phosphorylated + unphosphorylated) are taken to be a constant, the IGF1R 
levels are driven by the basal transcription rate (R.1) 
The descriptive pathway detailed above was converted to rate equations as below, 




 ;      IGF-2 binding of IGF1R and activation    R.2 
𝑣2 = 0.5𝑘2[𝑅𝑇𝑖𝑛𝑡] ; Internalized receptor complexes recycling back to the cell surface. R.3 




 ;  IGF2 binding and phosphorylation of the IGF1R: IR complex R.5 
𝑣5 = 𝑘5[𝑅𝑇𝑃] ;  Fraction of phosphorylated receptors that get internalized   R.6 
𝑣6 = 𝑘6[𝑅𝑇𝑖𝑛𝑡] ; Fraction of internalized receptors degraded via lysosomal and proteasomal 

























 ; Erk driven negative feedback onto itself    R.11 
𝑣11 = 𝐵𝑡𝑟 ∗ (𝐸𝑟𝑘_𝑓𝑏_𝑑𝑒𝑙𝑎𝑦) ;  A delayed Erk driven positive transcriptional feedback on IGF1R 
           R.12 
Where [𝐼𝐺𝐹1𝑅] and [𝐼𝐺𝐹1𝑅: 𝐼𝑅] are the total cell surface receptors, [𝑅𝑇𝑃] and [𝑅𝑇𝑖𝑛𝑡] are the 
activated cell surface and internalized receptors respectively, [Akt] and [Erk] are non-
phosphorylated Akt and Erk while �𝐴𝑘𝑡𝑝𝑝� and [𝐸𝑟𝑘𝑝𝑝] are the phosphorylated Akt and Erk. Btr 
is the basal transcription rate, while [Lig] is IGF-2. The parameters used in the equations are 
listed below in Table. 1 along with the method used to estimate them. 
Table 1 : Parameters used in the rate equations (R.1 to R.12) - Values and method of estimation. 
Parameters Value  ( Mean ± SD )   Method 
Btr 3000 / sec Estimate from data fitting 
𝑘1 1 / sec Conversion factor 
𝐾1 50 nM (Surinya et al., 2008),(Forbes 
et al., 2002),(Danielsen et al., 
1990) 
𝑘2 0.01 / sec Estimate from data fitting 
𝑘3 0.0005 /sec Estimate from data fitting 
𝑘4 1 /sec Conversion factor 
𝐾4 50 nM (Surinya et al., 2008),(Forbes 
et al., 2002),(Danielsen et al., 
1990) 
𝑘5 0.9 /sec Estimated from data fitting 
and bound experimentally 
𝑘6 0.01 /sec Estimate from data fitting 
𝑘7 13.2± 3.9 /sec Estimate from data fitting 
𝐾7 75.3 ± 24.9 nM Estimate from data fitting 
𝑘8 0.7 ± 0.2 /sec Estimate from data fitting 




𝑘9 0.4 ± 0.1  /sec Estimate from data fitting 
𝑘10 (1.5 ± 0.8) x 10
3 /sec Estimate from data fitting 
𝐾10 0.14 ± 0.03 nM
 Estimate from data fitting 
𝑁1 3.5
 Estimate from data fitting 
𝑁2 3.5 Estimate from data fitting 
 
ODE equations for implementation of model : The model described above was implemented by 
a system of ordinary differential equations (ODE) listed below. The behavior of the model was 
studied by numerically solving the system of ODEs.  
𝑑[𝐼𝐺𝐹1𝑅]
𝑑𝑡
= 𝑣0 − 𝑣1 + 𝑣2 − 𝑣3 + 𝑣11       O.1 
𝑑[𝐼𝐺𝐹1𝑅:𝐼𝑅]
𝑑𝑡
= 𝑣0 − 𝑣4 + 𝑣2        O.2 
𝑑�𝑅𝑇𝑝�
𝑑𝑡
= 𝑣1 + 𝑣4 − 𝑣5         O.3 
𝑑[𝑅𝑇𝑖𝑛𝑡]
𝑑𝑡
=  −2𝑣2 + 𝑣5 − 𝑣6        O.4 
𝑑�𝐴𝑘𝑡𝑝𝑝�
𝑑𝑡
= 𝑣8 − 𝑣7         O.5 
𝑑[𝐴𝑘𝑡]
𝑑𝑡
= 𝑣7 − 𝑣8         O.6 
𝑑[𝐸𝑟𝑘𝑝𝑝]
𝑑𝑡
= 𝑣9 − 𝑣10         O.7 
𝑑[𝐸𝑟𝑘]
𝑑𝑡
= 𝑣10 − 𝑣9         O.8 
The system of ODE equations was written and implemented in Matlab Ver R2011b. The 




state from the initial conditions listed in Table 2 by running the simulation with no ligand input ( 
[IGF-2]=0) until all variables attained a constant concentration. 
 
Table 2 : Initial values for system variables 
Molecular Species Value Reference 
𝐼𝐺𝐹1𝑅 75 x 103 (Wiley et al., 2003) 
𝐼𝐺𝐹1𝑅: 𝐼𝑅 50 x 103 Measured relative to IGF1R 
𝑅𝑇𝑝 0  
𝑅𝑇𝑖𝑛𝑡 0  
𝐴𝑘𝑡 100 nM (Barnett et al., 2005), 
(Hatakeyama et al., 2003) 
𝐴𝑘𝑡𝑝𝑝 0 nM  
𝐸𝑟𝑘 2000 nM From (Hatakeyama et al., 
2003) 
𝐸𝑟𝑘𝑝𝑝 0 nM  
𝑃𝑃2𝐴 10 nM From (Hatakeyama et al., 
2003) 
 
The model equations were written in Matlab ver R2011b and the system of ODE equations 
solved using custom written code. To define an initial steady state for the system analogous to 
serum starving of cells, the model was simulated starting from the values listed in Table 2 and 
allowed to run until all variables settled to a constant value. These values were used as the 
initial steady state of the system prior to stimulation by IGF-2.  
Model Training : To train the model and to estimate the parameters listed in Table 1, the fold 
increase in pAkt and pErk activation in response to IGF-2 stimulation (Fig 1.1A  ), were used. For 
a given set of model parameters the model output (pAKt and pErk) was computed as a function 
of time. The model parameter estimation was set up as a minimization of the sum of the mean 
square error of the model output and the experimental values of both pAkt and pErk (T.1)  
min
∀ 𝑀𝑜𝑑𝑒𝑙 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠
�{𝑀𝑜𝑑𝑒𝑙(𝑝𝐴𝑘𝑡) − 𝐸𝑥𝑝(𝑝𝐴𝑘𝑡)}2 + {𝑀𝑜𝑑𝑒𝑙(𝑝𝐸𝑟𝑘) − 𝐸𝑥𝑝(𝑝𝐸𝑟𝑘)}2 
           T.1 
The Direct (Divided Rectangles) algorithm (D. R. Jones, 1993) based on a modified Lipschitzian 
optimization was the algorithm used to minimize the above cost function.  The estimation was 
done for all the three sets of data used in Fig 1.1A.  The mean and standard deviation (SD) of 
each of the parameters are listed in Table 1. The model output of pAkt and pErk profiles trained 




model,  the model output using the mean of the estimated parameters was compared against 
the mean of the 3 sets of data used in training. The comparison is plotted in red for Akt and Erk 
on the right side of Fig 3E. To test the predictive ability of the model we simulated WT behavior 
by using WT values of receptors (both IGF1R and IGF1R:IR heterotetramers) and internalization 
rate only as shown in Table 3. The rest of the parameters were kept the same as before. The 
model output simulating WT fold increase in pAkt and pErk compared with experimental pAkt 
and pErk data for WT cells from Fig 1.1A is shown in blue in the right panel of Fig 1.11 
Table 3 : Parameters /  Variables changed in model to predict WT behavior. 
Parameters/Variables Relevance Value Reference 
IGF1R Initial Value 30x103 Measured experimentally 
IGF1R:IR Initial Value 15x103 Measured experimentally 
𝑘5 Internalization rate 0.01 /sec Measured experimentally 
 
The positive transcriptional feedback of Erk onto IGF-1R (Fig 3A) is implemented as below. 
𝐸𝑟𝑘_𝑓𝑏_𝑑𝑒𝑙𝑎𝑦 = �






𝑓𝑜𝑟 12 < 𝑡 ≤ 24ℎ𝑟𝑠 
Anti and Pro-apoptotic extension of IGF-2 signaling model :  As shown in Fig. 4A and Fig. 4B, 
Bax and Bcl2 levels in LOI cells share a reciprocal relationship with the Bax and Bcl2 levels in WT 
cells. The computational model for IGF-2 signaling was extended to simulate steady levels of Bax 
and Bcl2. As shown in Fig 4D, Bax steady state levels depend on the strength of Erk signaling 
while it has been shown before and in Supp Fig XX that Bcl2 levels depend on the strength of Akt 
signaling.  
[𝐵𝑎𝑥] = 𝑘𝐵𝑎𝑥 ∗ 𝑚𝑎𝑥(𝑝𝐸𝑟𝑘) 
[𝐵𝑐𝑙2] = 𝑘𝐵𝑐𝑙2 ∗ 𝑚𝑎𝑥(𝑝𝐴𝑘𝑡) 
To estimate values of kbax and kbcl2 the steady state values of Bax and Bcl2 had to be 
established. Various estimates of Bax and Bcl2 values in mammalian cells put the concentration 
in between 1 and 10nM[refx][refy][refz]. The following is also known, 
[𝐵𝑐𝑙2𝑊𝑇] = 2 ∗ [𝐵𝑐𝑙2𝐿𝑂𝐼] 
[𝐵𝑎𝑥𝑊𝑇] = 0.5 ∗ [𝐵𝑎𝑥𝐿𝑂𝐼] 
Using the condition for survival of a cell in terms of pro and anti apoptotic proteins, 
For every [0 ≤ 𝐵𝑐𝑙2𝐿𝑂𝐼 ≤ 10𝑛𝑀, 0 ≤ 𝐵𝑎𝑥𝐿𝑂𝐼 ≤ 10𝑛𝑀]𝑡ℎ𝑎𝑡 𝑠𝑎𝑡𝑖𝑠𝑓𝑖𝑒𝑠, [𝐵𝑐𝑙2𝐿𝑂𝐼] ≥ [𝐵𝑎𝑥𝐿𝑂𝐼] 





The Bcl2,Bax values of WT and LOI cells that satisfy the above equations form a triangular region 
as shown in Fig 5A. The centroids of these regions are taken as the steady state values of Bax 
and Bcl2 for WT and LOI cells respectively. 
 
Table 4 : Steady state values of Bax, Bcl2 and associated constants 
WT LOI 
Bcl2 6.6nM Bcl2 3.3nM 
Bax 1.3nM Bax 2.6nM 
KBcl2 0.55nM KBcl2 0.55nM 
KBax 0.33nM KBax 0.3nM 
 
Model learning and prediction of IGF-1 signaling : To simulate IGF-1 modeling, as with IGF-2, 
the model was trained on the fold increase in pAkt and pErk of LOI cells in response to IGF-1 Fig 
6A. The model learning is also shown in Fig 6A. The Kd of binding of IGF-1 to the cell surface 
receptor complexes of IGF1R and IGF1R:IR was kept as 1/10th that of IGF-2 binding during the 
training (Surinya et al., 2008). To predict WT Akt and Erk responses, the internalization rate of 
the receptors in WT model was varied until the model prediction matched the experimental 
data Fig 6B. The IGF-1 binding values to the cell surface receptor complexes and the 
Internalization rate used to predict WT responses are shown in Table 5. 
Table 5 : Parameter comparison between IGF-1 and IGF-2 signaling models. 
IGF-1 IGF-2 
WT LOI WT LOI 
Internalization rate Internalization rate 
k5 0.5 k5 0.9 k5 0.01 k5 0.9 
Kd of Binding IGF1R IGF1R:IR Kd of Binding IGF1R IGF1R:IR 
K1 5nM 5nM K1 50nM 50nM 










Figure S 1 : Receptor expression  
Exponentially growing LOI and WT cells were harvested and A) analysed by Western blots for A) 
total IGF-1R levels.  B) Cell lysates were immunoprecipitated with IGF-1R antibodies and 





Figure S 2 : Fold increase in pErk and pAkt 
Exponentially growing LOI and WT cells were serum starved overnight and stimulated with IGF-2 
for 10 minutes and fixed on glass coverslips and analysed by immunofluorescence for fold 





Figure S 3 : Total Akt and Erk 
Exponentially growing LOI and WT cells were harvested and analysed by Western blots for 






Figure S 4 : Multiple WT and LOI lines 
4 different LOI cell lines and 4 different WT cell lines were extracted from E16 mouse embryos. 
These cell lines were passaged for 3 to 4 times. Exponentially growing cells (75 to 80% 
confluency) were serum starved overnight, stimulated with 100ng/ml IGF-2 for 10 minutes, 





Figure S 5 : Multiple cell lines quantification 
4 different LOI cell lines and 4 different WT cell lines were extracted from E16 mouse embryos. 
These cell lines were passaged for 3 to 4 times. Exponentially growing cells (75 to 80% 
confluency) were serum starved overnight, stimulated with 100ng/ml IGF-2 for 10 minutes, 
harvested and analyzed by Western blots for pAkt and pErk expression.  
 




WT and LOI cells were grown on cover slips to confluency. The cells were labelled for 15 min at 
4degC with the dye FM-143 that labels the plasma membrane and then washed to remove 
excess dye. The cells were then treated with 100ng/ml IGF-2 to allow for internalization of the 
dye for the indicated timepoints.  The cells are then fixed and the amount of internalized dye 
quantified using Immunofluorescence.  
 
Figure S 7 : β-Arrestin and Mdm2  
Exponentially growing WT and LOI cells were harvested and analyzed by Western blotting for 





Figure S 8 : cMyc induction and expression 
 A) Exponentially growing LOI cells were serum starved overnight, stimulated with IGF-2 for the 
indicated time points, harvested and analyzed by qRT-PCR for cMyc expression.  cMyc 
expression was normalized to β-Actin in each well and plotted as fold increase over the value at 
time=0. cMyc is a direct target of IGF1R signaling. Akt-Erk signaling balance is reflected in cMyc 
levels : B) Exponentially growing WT and LOI cells were serum starved overnight and stimulated 
with 10%FBS for 24 hours, they were then harvested in lysates and analyzed by Western 
blotting.  cMyc levels in the LOI cells reflect the increased Erk signaling in LOI cells vis-a-vis the 
WT cells. Pro-apoptotic Bax is a cMyc target :  C) LOI cells were serum starved overnight and 
then treated with varying concentrations of U0126 (Mek inhibitor) for 60 min followed by IGF-2 
for 24 hours. The cells were harvested in lysates and analyzed via Western blotting. Bax 





Figure S 9 : Bcl2 levels are affected by Akt signaling 
Exponentially growing LOI cells were treated with various doses of the Pi3K inhibitor, LY294002 






Figure S 10: Bcl2 levels are not affected by Erk signaling 
Exponentially growing LOI cells were treated with various doses of the Erk inhibitor, U0126 for 60 minutes, stimulated 





Figure S 11 : Activated Caspase-9 and -3   
WT and LOI cells were serum starved and treated with 5µM NVPAEW541 for the indicated time 
points, harvested in lysates and analyzed by Western Blotting for activated Caspase-9 and 
Caspase-3. Both the early Caspase-9 and the effector Caspase-3 are seen to activated by t=5 
hours in LOI cells while no activation is seen in WT cells. 
 




Exponentially growing LOI cells were serum starved overnight and treated with 5µM 
NVPAEW541 for the indicated time points and stained for the early apoptosis marker Annexin V. 
By 5 hours after NVP treatment, LOI cells show Annexin V positive stain. 
 
 
Figure S 13: IGF-2 expression 
Exponentially growing LOI and WT cells were analyzed by qRT-PCR for IGF-2 mRNA expression.  
LOI cells show increased expression of IGF-2 
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